Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/twist-bioscience-corp">Twist Bioscience </a>is a market leader in the synthetic biology space, leveraging a proprietary silicon-based DNA synthesis platform that provides a significant cost and throughput advantage over traditional methods.</li>
 <li>The company is demonstrating a strong growth trajectory with rapidly increasing revenues and improving gross margins, driven by expanding its core synthetic DNA business and growing its presence in Next-Generation Sequencing (NGS) tools and Biopharma services.</li>
 <li>Despite its technological leadership and revenue growth, the company has a history of significant net losses and negative cash flow. The path to sustained profitability remains a key focus, with the company guiding towards achieving adjusted EBITDA breakeven.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Twist Bioscience is a market leader in the synthetic biology space, leveraging a proprietary silicon-based DNA synthesis platform that provides a significant cost and throughput advantage over traditional methods.
  The company is demonstrating a strong growth trajectory with rapidly increasing revenues and improving gross margins, driven by expanding its core synthetic DNA business and growing its presence in Next-Generation Sequencing (NGS) tools and Biopharma services.
  Despite its technological leadership and revenue growth, the company has a history of significant net losses and negative cash flow. The path to sustained profitability remains a key focus, with the company guiding towards achieving adjusted EBITDA breakeven.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Twist Bioscience  (TWST US) - Aug 2026

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

iShares PHLX Semiconductor ETF / Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.</li>
<li>We continue to believe Technology and A.I. areas (XLK, SOXX, DRAM) are poised to move higher, and we have Technology on watch for a potential upgrade to overweight.</li>
<li>A significant "wall of worry" is being built, with the latest bricks being bad breadth and rising interest rate volatility</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.
We continue to believe Technology and A.I. areas (XLK, SOXX, DRAM) are poised to move higher, and we have Technology on watch for a potential upgrade to overweight.
A significant "wall of worry" is being built, with the latest bricks being bad breadth and rising interest rate volatility


Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern? All Hinges on 7507-7580 SPX

Healthcare Analyst

Wilfred Yuen

Thematic (Sector/Industry)

<ul>
<li>For World Lung Cancer Conference (WCLC 2026), we wrap-up key data updates, covering drugs from Akeso/SMMT, Hansoh/GSK, MediLink/Roche, RemeGen/AbbVie, Leads Biolabs, GenFleet, CSPC, Hengrui, and Henlius
</li>
<li>AI drugs news flow: 1) Lilly Tunelab announced agreements with Genscript, Twist, Gingko; 2) Harbour Bio developed world's first language model for heavy-chains-only antibodies; 3) ByteDance's Anew Labs raised US$290m</li>
<li>Other updates include LEGN's new CEO appointment, Chimagen/GSK licensing deal, China's 5-year plan for pharmaceutical industry</li>
</ul>


For World Lung Cancer Conference (WCLC 2026), we wrap-up key data updates, covering drugs from Akeso/SMMT, Hansoh/GSK, MediLink/Roche, RemeGen/AbbVie, Leads Biolabs, GenFleet, CSPC, Hengrui, and Henlius

AI drugs news flow: 1) Lilly Tunelab announced agreements with Genscript, Twist, Gingko; 2) Harbour Bio developed world's first language model for heavy-chains-only antibodies; 3) ByteDance's Anew Labs raised US$290m
Other updates include LEGN's new CEO appointment, Chimagen/GSK licensing deal, China's 5-year plan for pharmaceutical industry


<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). </li>
<li>Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).</li>
<li>With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM). 
Additionally, we continue to believe the bottom is in for SPX, IWM, QQQ, and Technology areas (XLK, IGV, SOXX, CHAT).
With that said, some mixed price action in A.I. themes -- notably semiconductors (SOXX), generative A.I. (CHAT), memory (DRAM), and neoclouds (WGMI) -- are giving us some reason for pause.


Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

<ul>
<li>
1H26 results driven by AI orders, with life sciences segment revenue up 26% YoY (or +16% HoH) and adjusted operating profit up 103% YoY to US$94m.</li>
<li>
2026 guidance upgrade: 1) Life science: 25-30% revenue growth (vs. 15-18% prior), with adjusted OPM: 25%+ (vs. 19% prior); 2) Probio: 25-30% fee-for-service revenue growth (vs. 20-25% prior)</li>
<li>
At US$7.2bn mkt cap (vs. TWST: US$7.4bn), our back-of-envelop calculation indicates ~36x 2027E P/E. Genscript holds net cash of US$638m and 45% stake in LEGN. See inside for call takeaways</li>
</ul>



1H26 results driven by AI orders, with life sciences segment revenue up 26% YoY (or +16% HoH) and adjusted operating profit up 103% YoY to US$94m.

2026 guidance upgrade: 1) Life science: 25-30% revenue growth (vs. 15-18% prior), with adjusted OPM: 25%+ (vs. 19% prior); 2) Probio: 25-30% fee-for-service revenue growth (vs. 20-25% prior)

At US$7.2bn mkt cap (vs. TWST: US$7.4bn), our back-of-envelop calculation indicates ~36x 2027E P/E. Genscript holds net cash of US$638m and 45% stake in LEGN. See inside for call takeaways


Genscript (1548.HK): 1H26 Results Driven by AI Orders; Guidance Upgrades on Life-Science and Probio

United States

Twist Bioscience Corporation operates as a biotechnology company. The Company specializes in synthetic DNA such as biodetection, functional genomics, genome engineering, drugs and biodefense, and data storage. Twist Bioscience serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Twist Bioscience (TWST US)

Primer: Twist Bioscience (TWST US) - Aug 2026

Twist Bioscience is a market leader in the synthetic biology space, leveraging a proprietary silicon-based DNA synthesis platform that provides...

αSK Primers

Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern? All Hinges on 7507-7580 SPX

Interest Rate Volatility, High Yield Spreads, and Bad Breadth a Concern?; All Hinges on 7507-7580 $SPX. We continue to believe Technology and A.I....

Vermilion Research

China Healthcare Weekly Wrap (14-18 Sep)

Key news over the week: 1) WCLC cancer conference updates, 2) AI news flows (TuneLab/Genscript, Harbour Bio, ByteDance's Anew Labs), 3)others:...

Wilfred Yuen

Mixed Signals in A.I. Names (SOXX, CHAT, DRAM, WGMI); Bullish Outlook Intact

Mixed Signals in A.I. Names ($SOXX $CHAT $DRAM $WGMI); Bullish Outlook Intact $SPX $QQQ $IWM. $CHAT breaking above the 50-day MA likely signaling...

Vermilion Research

Genscript (1548.HK): 1H26 Results Driven by AI Orders; Guidance Upgrades on Life-Science and Probio

1H26 results driven by AI orders; 2026 guidance upgrade on Life science and Probio; at US$7.2bn mkt cap (vs TWST: US$7.4bn), our quick back-of...

Wilfred Yuen

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)